Biopep Malaysia Sdn Bhd

Biopep Malaysia Sdn. Bhd. is a wholly-owned subsidiary of Biopep Solutions Inc., Canada. The parent company, Biopep Solutions Inc., Canada, discovers, develops and manufactures innovative therapeutic products for the treatment of human diseases. Biopep Malaysia focuses on the extraction of Leech Saliva Extract (LSE) from different species of leeches found in Malaysia to be used for treatment of several types of cancer. The parent company has successfully received US patent protection for its product, LSE, as a treatment for various types of cancers and has an additional pending patent for worldwide protection on the use of LSE to treat cancer.

It focuses its activity on BPS-001 production. In order to ensure a sustainable supply of Malaysian leeches, Hirudinaria manillensis, the raw material used for production of BPS-001, Biopep Malaysia had signed a MOA with HUSNA Hirudinaria Agro Farm (HUSNA) in March 2015. HUSNA operates a leech farm in Rawang, Selangor.

Biopep Malaysia had also signed a Lease with UPM (Universiti Putra Malaysia) – Malaysian Technology Development Corporation (MTDC) to secure a seven-unit premises for its incubator complex at the UPM-MTDC Technology Centre III at Serdang, Selangor. The production and manufacturing facilities include Administrative Offices, Laboratories for Leech Holding, Leech Saliva Extraction, and Quality Control, Production (Freeze Drying/Deep Freezing), pilot Leech Breeding facilities and R&D activities.


Biopep Solutions Inc. is a privately owned, development-stage biotechnology company that discovers and develops innovative therapeutic products for the treatment of cancers and other diseases. The Company’s lead product, BPS-001, is a heterogeneous biologic extract containing a known composition of multiple peptide and protein components. BPS-001 is produced from Leech Saliva Extract using patented extraction processes and proprietary technology. The objective of the Company is to develop the use of BPS-001 over the next three years to treat several forms of cancers.

Currently, Biopep Solutions is actively pursuing clinical trials for the use of BPS-001 as a treatment for metastatic, castration resistant prostate cancer (mCRPC).

Pre-clinical pharmacological studies and the preliminary Chemistry, Manufacturing and Control (CMC) specifications have been completed and we anticipate earning approval of an Investigational New Drug Application (IND) from the US, FDA and a Clinical Trial Application (CTA) from Health Canada to proceed with phase 1/2 clinical testing.

The chemical characterization and preclinical studies suggest that BPS-001 contains multiple active components eliciting activities that interfere with carcinogenesis by: inhibiting angiogenesis, increasing apoptosis of cancer cells; and, by exhibiting anti-inflammatory properties. Thus, unlike currently approved molecularly targeted agents, BPS-001 has multivalent mechanisms that act by blocking more than one target that contributes to carcinogenesis.

Please go to this website: for further details.